Literature DB >> 2986937

Amiodarone. Biochemical aspects and haemodynamic effects.

J P Gagnol, C Devos, M Clinet, P Nokin.   

Abstract

The mechanisms underlying the non-competitive beta-antagonistic properties of amiodarone were investigated, and the haemodynamic responses to exercise following the administration of oral amiodarone or intravenous propranolol were compared in dogs with a healed myocardial infarction submitted to a graded treadmill exercise. In radioligand binding studies, amiodarone, up to 10 mumol/L did not compete with 125I-iodocyanopindolol for binding to rat heart beta-adrenoceptors. Exposure of cardiac membranes to greater concentrations of amiodarone induced a significant decrease in the number of beta-adrenoceptors without affecting their affinity for 125I-iodocyanopindolol. Similar results were observed ex vivo, in rats after single or multiple dose administration. When added in vitro to rat heart membranes, amiodarone non-competitively inhibited the activation of adenylate cyclase by isoprenaline, glucagon and secretin. Stimulation of adenylate cyclase by those agents which act at more internal sites in the sarcolemmal membrane such as GppNHp, sodium fluoride or forskolin, was much less affected by amiodarone. In dogs performing at a submaximal work level, amiodarone significantly reduced heart rate and tended to increase coronary flow and to reduce left ventricular end-diastolic pressure, but did not affect left ventricular dP/dt. During submaximal exercise, propranolol had similar effects on heart rate, but dramatically reduced myocardial contractility.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2986937     DOI: 10.2165/00003495-198500293-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  30 in total

1.  Thyroxine and propylthiouracil effects on alpha- and beta-adrenergic receptor number, ATPase activities, and sialic acid content of rat cardiac membrane vesicles.

Authors:  M M McConnaughey; L R Jones; A M Watanabe; H R Besch; L T Williams; R J Lefkowitz
Journal:  J Cardiovasc Pharmacol       Date:  1979 Nov-Dec       Impact factor: 3.105

2.  Hemodynamic effects of intravenous amiodarone in patients with depressed left ventricular function and recurrent ventricular tachycardia.

Authors:  A Schwartz; E Shen; F Morady; K Gillespie; M Scheinman; K Chatterjee
Journal:  Am Heart J       Date:  1983-10       Impact factor: 4.749

3.  Comparative profile of L 3428 and other antianginal agents on cardiac hemodynamics.

Authors:  J M Petta; V J Zaccheo
Journal:  J Pharmacol Exp Ther       Date:  1971-02       Impact factor: 4.030

4.  Effects of amiodarone and L8040, novel antianginal and antiarrhythmic drugs, on cardiac and coronary haemodynamics and on cardiac intracellular potentials.

Authors:  B N Singh; D E Jewitt; J M Downey; E S Kirk; E H Sonnenblick
Journal:  Clin Exp Pharmacol Physiol       Date:  1976 Sep-Oct       Impact factor: 2.557

5.  Secretin and VIP-stimulated adenylate cyclase from rat heart. I. General properties and structural requirements for enzyme activation.

Authors:  P Chatelain; P Robberecht; P De Neef; M Deschodt-Lanckman; W König; J Christophe
Journal:  Pflugers Arch       Date:  1980-12       Impact factor: 3.657

6.  Effect of amiodarone on serum triiodothyronine, reverse triiodothyronine, thyroxin, and thyrotropin. A drug influencing peripheral metabolism of thyroid hormones.

Authors:  A Burger; D Dinichert; P Nicod; M Jenny; T Lemarchand-Béraud; M B Vallotton
Journal:  J Clin Invest       Date:  1976-08       Impact factor: 14.808

7.  Studies of amiodarone during experimental myocardial infarction: beneficial effects on hemodynamics and infarct size.

Authors:  L W DeBoer; J J Nosta; R A Kloner; E Braunwald
Journal:  Circulation       Date:  1982-03       Impact factor: 29.690

8.  Hypotensive action of commercial intravenous amiodarone and polysorbate 80 in dogs.

Authors:  W B Gough; R H Zeiler; P Barreca; N El-Sherif
Journal:  J Cardiovasc Pharmacol       Date:  1982 May-Jun       Impact factor: 3.105

9.  Hyperthyroxinemia with bradycardia and normal thyrotropin secretion after chronic amiodarone administration.

Authors:  S Melmed; K Nademanee; A W Reed; J A Hendrickson; B N Singh; J M Hershman
Journal:  J Clin Endocrinol Metab       Date:  1981-11       Impact factor: 5.958

Review 10.  Amiodarone: historical development and pharmacologic profile.

Authors:  B N Singh
Journal:  Am Heart J       Date:  1983-10       Impact factor: 4.749

View more
  3 in total

1.  Amiodarone is a potent calmodulin antagonist.

Authors:  P Nokin; J P Blondiaux; P Schaeffer; L Jungbluth; C Lugnier
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-04       Impact factor: 3.000

2.  Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the beta-adrenoceptor and adenylate cyclase in rat heart.

Authors:  P Chatelain; L Meysmans; J R Mattéazzi; P Beaufort; M Clinet
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

3.  Clinical, haemodynamic, and antiarrhythmic effects of long term treatment with amiodarone of patients in heart failure.

Authors:  J G Cleland; H J Dargie; I N Findlay; J T Wilson
Journal:  Br Heart J       Date:  1987-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.